| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 1949520 | Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids | 2011 | 7 Pages |
Fenofibrate, a drug in the fibrate class of amphiphathic carboxylic acids, has multiple blood lipid modifying actions, which are beneficial to the prevention of atherosclerosis. One of its benefits is in lowering fasting and postprandial blood triglyceride (TG) concentrations. The goal of this study was to determine whether the hypotriglyceridemic actions of fenofibrate in the postprandial state include alterations in TG and fatty acid metabolism in the small intestine. We found that the hypotriglyceridemic actions of fenofibrate in the postprandial state of high-fat (HF) fed mice include a decrease in supply of TG for secretion by the small intestine. A decreased supply of TG for secretion was due in part to the decreased dietary fat absorption and increased intestinal fatty acid oxidation in fenofibrate compared to vehicle treated HF fed mice. These results suggest that the effects of fenofibrate on the small intestine play a critical role in the hypotriglyceridemic effects of fenofibrate.
Research Highlights► Fenofibrate decreases postprandial triglyceride secretion from enterocytes. ► Fenofibrate increases fatty acid oxidation in enterocytes. ► Fenofibrate decreases quantitative dietary fat absorption.
